1. Clinical, subclinical characteristics and relationship between the concentration of carcinoembryonic antigen, fragment of cytokeratin 19, squamous cell carcinoma antigen plasma in patients with non small cell lung cancer
Main Article Content
Abstract
This study was conducted to examine the clinical, subclinical characteristics and relationship between the concentrations of CEA, CYFRA 21-1, and SCC plasma in 250 patients with non-small cell lung cancer diagnosed and treated as inpatients at the National Lung Hospital from May 2024 to May 2025. Results: The median concentrations of CEA, CYFRA 21-1, and SCC plasma with stage IV were highest , 20.25; 4.5; 5.15 ng/ml, respectively. The difference was statistically significant with p < 0.05. The median CEA concentration of the Adenocarcinoma was highest by 12.5 ng/ml with p < 0.05. The median CYFRA 21-1 concentration of the Squamous Cell Carcinoma was highest by 5.76 ng/ml with p > 0.05; The median SCC concentration of the Squamous Cell Carcinoma was highest by 5.25 vs 1.1 ng/ml with p < 0.05. The average concentration of CEA, CYFRA 21-1, and SCC were highest in NSCLC patients at 141.55 ± 342.92; 19.22 ± 47.28; 21.54 ± 3.11ng/ml, respectively. Notably, there was statistical significance with p < 0.05.
Article Details
Keywords
CEA, CYFRA 21-1, SCC, clinical, subclinical characteristics, NSCLC
References
2. Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
3. Vietnamnet global. Vietnam’s lung cancer crisis: Most cases found too late. Vietnam Lung Health Access Program. March 26. https://vietnamnet.
4. PearlPoint Cancer Support. Lung cancer Handbook. 2014. www.lungcancer.org (800) 813-HOPE (4673).
5. Wang R et al. Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer. BioMed Research International; 2013(1): 195692. doi:10.1155/2013/195692.
6. Wang J., et al. Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. Transl Oncol. 2018; 11(4): 999-1006.
7. Bộ Y tế. Quyết định 4825/QĐ-BYT 2018 tài liệu chuyên môn Hướng dẫn chẩn đoán và điều trị ung thư phổi.
8. Bello MGD et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. Journal of Translational Medicine. 2019; 17: 74. doi:10.1186/s12967-019-1828-0.
9. Tống Quốc Đồng. The concentration of CEA and Cyfra 21-1 in patients with non-small cell lung cancer treated with tyrosine kinase inhibitors. SCIREA Journal of Medicine. 2021; 5(6): 62-74. doi:10.54647/pm31142.
10. American Cancer Society. About Lung Cancer. cancer.org | 1.800.227.2345. January 16, 2025.
11. Jiang C, Zhao M, Hou S, et al. The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer. Cancers. 2022; 14(20): 5064. doi:10.3390/cancers14205064.
12. Emad A Abd. Prognostic Value of CYFRA 21-1 and Carcinoembryonic Antigen in Non-Small Cell Lung Cancer. J Clin Cell Immunol. 2015; 06(02). doi:10.4172/2155-9899.1000316.
13. Chen S et al. Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer. Published online January 11, 2022. doi:10.21203/rs.3.rs-1145818/v2.